Related Experiment Video
Updated: May 14, 2025
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Chronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India
Pawan Kumar1, Arindam Ray2, Amrita Kumari2
1Immunization Division, Ministry of Health & Family Welfare, Government of India, New Delhi 110011, India.
Insights
India
Area of Science:
- Public Health
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Pneumonia is a leading cause of mortality in children under five globally, with approximately 700,000 deaths annually.
- The Indian Ministry of Health and Family Welfare (MoHFW) implemented a nationwide phased rollout of the pneumococcal conjugate vaccine (PCV) by 2021.
- The PCV campaign achieved nationwide coverage despite significant challenges, including the COVID-19 pandemic.
Purpose of the Study:
- To review the key decisions, processes, and stakeholder collaborations instrumental in the successful nationwide rollout of PCV in India.
- To highlight the strategies employed to overcome implementation hurdles, particularly during the COVID-19 pandemic.
Main Methods:
- A comprehensive desk review was conducted, analyzing published and unpublished literature.
- The review focused on pneumonia burden, PCV efficacy and effectiveness, and documentation of PCV introduction and scale-up in India.
Main Results:
- PCV coverage in India has shown a steady increase since the nationwide rollout in 2021.
- World Health Organization (WHO) and UNICEF estimates indicate a significant rise in PCV booster coverage from 25% in 2021 to 83% in 2023.
- These coverage rates align with the objectives of the WHO and UNICEF's Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD).
Conclusions:
- The phased nationwide PCV rollout, led by the MoHFW, was an ambitious initiative successfully executed despite the COVID-19 pandemic.
- Strong collaboration among the MoHFW, development partners, and stakeholders was crucial for navigating the complexities of the rollout.
- Further research into PCV's impact on antibiotic resistance and its economic benefits is recommended to support sustained funding and procurement decisions.
Background:
Globally, pneumonia claims the lives of about 700,000 children under the age of 5 every year. Pneumococcal conjugate vaccine (PCV) was introduced in India phase-wise, beginning in high-burden states, and the rollout was completed nationwide by 2021-representing a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite the challenges posed by the COVID-19 pandemic, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, processes, and coordinated efforts of the various stakeholders involved that led to this successful PCV rollout.
Methodology:
A comprehensive desk review of both published and unpublished literature relevant to pneumonia burden and the efficacy and effectiveness of PCVs, along with documentation of PCV introduction and the scale-up was carried out.
Results:
The documentation of the PCV journey has been broken down into four sections: pre-introduction, PCV Phase-I introduction, pan-India rapid expansion, and the period post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased, reflecting successful immunization efforts. WUENIC, which is an annual WHO, and UNICEF estimates of national immunization coverage also show a positive trend in vaccination coverage (PCV booster coverage = 25% (2021), rising to 83% (2023), aligning with the goals of the WHO and UNICEF's Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD).
Conclusions:
The phased rollout was an ambitious effort by the MoHFW, which was particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, along with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. Future studies on the role of PCVs in reducing antibiotic resistance and the economic benefits of PCV introduction could help policymakers sustain funding and prioritize vaccine procurement decisions.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
16:56Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:51Vaccinations
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause: